Joyce Bumgardner
Psychiatry · Sapulpa, OKNPI 1497815187
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.6% of the total across 163 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 14 manufacturers reported payments, led by Johnson & Johnson at 44.2% of the total. Reporting peaked in 2019 at $2,668 and has fallen 61.6% since, to $1,024 in 2025. Among psychiatry clinicians in OK with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 163 payments — averaging $48.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$4K
- Teva Pharmaceuticals USA, Inc.$1K
- Alkermes, Inc.$885
- Otsuka America Pharmaceutical, Inc.$580
- Vanda Pharmaceuticals Inc.$563
- Neurocrine Biosciences, Inc.$418
- plus $631 from 8 others
What the payments were for
- Food & beverage$7,928100%
- Education$300%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 49 | $3,518 |
| Teva Pharmaceuticals USA, Inc. | 23 | $1,363 |
| Alkermes, Inc. | 23 | $885 |
| Otsuka America Pharmaceutical, Inc. | 12 | $580 |
| Vanda Pharmaceuticals Inc. | 28 | $563 |
| Neurocrine Biosciences, Inc. | 6 | $418 |
| AbbVie(2 entities) | 12 | $335 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $78 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $73 |
| E.r. Squibb & Sons, L.L.C. | 2 | $48 |
| Indivior Inc. | 3 | $48 |
| Axsome Therapeutics, Inc. | 1 | $19 |
| Ironshore Pharmaceuticals Inc. | 1 | $17 |
| Sunovion Pharmaceuticals Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- INVEGA SUSTENNA$2,634
- INVEGA TRINZA$1,881
- LYBALVI$839
- AUSTEDO$591
- ARISTADA$495
- INGREZZA$373
- ABILIFY MAINTENA$359
- Austedo XR$350
- SPRAVATO$241
- Fanapt$240
- VRAYLAR$229
- ARISTADA INITIO$124
- ABILIFY ASIMTUFII$123
- UZEDY$117
How this compares
$7,958 in reported general payments places this provider in the 90th percentile of 328 psychiatry providers in Oklahoma.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AustedoDeutetrabenazine | 11 | $53,671 |
| AristadaAripiprazole Lauroxil | 13 | $44,215 |
| Invega SustennaPaliperidone Palmitate | 15 | $29,288 |
| FanaptIloperidone | 11 | $22,783 |
| Aripiprazole | 16 | $4,968 |
| Quetiapine Fumarate | 64 | $1,240 |
| Clozapine | 19 | $1,073 |
| Hydroxyzine Pamoate | 38 | $720 |
| Olanzapine | 16 | $399 |
| Risperidone | 34 | $355 |
| Trazodone Hcl | 38 | $337 |
| Mirtazapine | 19 | $292 |
| Fluvoxamine Maleate | 13 | $274 |
| Oxcarbazepine | 14 | $219 |
| Buspirone Hcl | 12 | $139 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo | $1,363 | $53,67111 claims |
| Alkermes, Inc.Aristada | $885 | $44,21513 claims |
| Johnson & JohnsonInvega Sustenna | $3,518 | $29,28815 claims |
| Vanda Pharmaceuticals Inc.Fanapt | $563 | $22,78311 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 328 psychiatry providers in Oklahoma.
Other psychiatry in Sapulpa
- Robert MortonAda$1.9M
- Sarah LandTulsa$287K
- Willis HollowayOklahoma City$92K
- Adonis Al BotrosOklahoma City$73K
- Marvin PeytonOklahoma City$60K
- Charles LesterMuskogee$39K
- Josephine DeguzmanOklahoma City$38K
- Jennifer MorrisEdmond$26K
- Julia IrwinNorman$16K
- Bradley McClureTulsa$15K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.